Trial of Prazosin for Post-Traumatic Stress Disorder in Military Veterans
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
BACKGROUND: -adrenoreceptor antagonist, has been effective in alleviating nightmares associated with post-traumatic stress disorder (PTSD) in military veterans. METHODS: We recruited veterans from 13 Department of Veterans Affairs medical centers who had chronic PTSD and reported frequent nightmares. Participants were randomly assigned to receive prazosin or placebo for 26 weeks; the drug or placebo was administered in escalating divided doses over the course of 5 weeks to a daily maximum of 20 mg in men and 12 mg in women. After week 10, participants continued to receive prazosin or placebo in a double-blind fashion for an additional 16 weeks. The three primary outcome measures were the change in score from baseline to 10 weeks on the Clinician-Administered PTSD Scale (CAPS) item B2 ("recurrent distressing dreams"; scores range from 0 to 8, with higher scores indicating more frequent and more distressing dreams); the change in score from baseline to 10 weeks on the Pittsburgh Sleep Quality Index (PSQI; scores range from 0 to 21, with higher scores indicating worse sleep quality); and the Clinical Global Impression of Change (CGIC) score at 10 weeks (scores range from 1 to 7, with lower scores indicating greater improvement and a score of 4 indicating no change). RESULTS: A total of 304 participants underwent randomization; 152 were assigned to prazosin, and 152 to placebo. At 10 weeks, there were no significant differences between the prazosin group and the placebo group in the mean change from baseline in the CAPS item B2 score (between-group difference, 0.2; 95% confidence interval [CI], -0.3 to 0.8; P=0.38), in the mean change in PSQI score (between-group difference, 0.1; 95% CI, -0.9 to 1.1; P=0.80), or in the CGIC score (between-group difference, 0; 95% CI, -0.3 to 0.3; P=0.96). There were no significant differences in these measures at 26 weeks (a secondary outcome) or in other secondary outcomes. At 10 weeks, the mean difference between the prazosin group and the placebo group in the change from baseline in supine systolic blood pressure was a decrease of 6.7 mm Hg. The adverse event of new or worsening suicidal ideation occurred in 8% of the participants assigned to prazosin versus 15% of those assigned to placebo. CONCLUSIONS: In this trial involving military veterans who had chronic PTSD, prazosin did not alleviate distressing dreams or improve sleep quality. (Funded by the Department of Veterans Affairs Cooperative Studies Program; PACT ClinicalTrials.gov number, NCT00532493 .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“a position paper by the American Academy of Sleep Medicine (AASM) has highlighted a contradictory study [33] and downgraded its recommendation for prazosin, but still considers it to be the first-line pharmacological choice [34].”
From Nightmare Disorder and Isolated Sleep Paralysis (2021) · cites this paper as [33]
Citations
Cites
1 retracted
Pietrzak, R. H., Gallezot, J.-D., Ding, Y.-S., Henry, S., Potenza, M. N., Southwick, S. M., Krystal, J. H., Carson, R. E., & Neumeister, A. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.399 · Cited by 127
RetractedThe PHQ-9: Validity of a brief depression severity measure
Kroenke, K., Spitzer, R. L., & Williams, J. B. W. (2001) · Journal of General Internal Medicine · doi:10.1046/j.1525-1497.2001.016009606.x · Cited by 44,910
The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research
Buysse, D. J., Reynolds, C. F., Monk, T. H., Berman, S. R., & Kupfer, D. J. (1989) · Psychiatry Research · doi:10.1016/0165-1781(89)90047-4 · Cited by 35,234
Goodman & Gilman's The Pharmacological Basis of Therapeutics
Brunton, L. L. (1985) · Cited by 7,321
Bush, K. (1998) · Archives of Internal Medicine · doi:10.1001/archinte.158.16.1789 · Cited by 6,196
The development of a Clinician-Administered PTSD Scale
Blake, D. D., Weathers, F. W., Nagy, L. M., Kaloupek, D. G., Gusman, F. D., Charney, D. S., & Keane, T. M. (1995) · Journal of Traumatic Stress · doi:10.1002/jts.2490080106 · Cited by 5,024
Pocock, S. J., & Simon, R. (1975) · Biometrics · doi:10.2307/2529712 · Cited by 2,350
Substance Use Disorders in Patients With Posttraumatic Stress Disorder: A Review of the Literature
Jacobsen, L. K., Southwick, S. M., & Kosten, T. R. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.8.1184 · Cited by 1,041
Naltrexone in the Treatment of Alcohol Dependence
Krystal, J. H., Cramer, J. A., Krol, W. F., Kirk, G. F., & Rosenheck, R. A. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011127 · Cited by 618
Self-citationRaskind, M. A., Peskind, E. R., Kanter, E. D., Petrie, E. C., Radant, A., Thompson, C. E., Dobie, D. J., Hoff, D., Rein, R. J., Straits-Tröster, K., et al. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.2.371 · Cited by 607
Self-citation
Research works printed but not linked: 3
- Guy W. CDEU assessment manual for psychopharmacology. Rockville, MD: National Institute of Mental Health, 1976.
- Frisch MB. Manual and treatment guide for the Quality of Life Inventory (QOLI). Minneapolis: Pearson Assessments 1994.
- The Management of Posttraumatic Stress Disorder Working Group. VA/DoD clinical practice guideline for the management of posttraumatic stress disorder. Washington, DC: Department of Veterans Affairs, Department of Defense, 2010.
Cited by
Post-traumatic stress disorder: clinical and translational neuroscience from cells to circuits
Ressler, K. J., Berretta, S., Bolshakov, V. Y., Rosso, I. M., Meloni, E. G., Rauch, S. L., & Carlezon, W. A. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-022-00635-8 · Cited by 481
Complex post-traumatic stress disorder
Maercker, A., Cloitre, M., Bachem, R., Schlumpf, Y. R., Khoury, B., Hitchcock, C., & Bohus, M. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00821-2 · Cited by 428
A guide to guidelines for the treatment of posttraumatic stress disorder in adults: An update
Hamblen, J. L., Norman, S. B., Sonis, J. H., Phelps, A. J., Bisson, J. I., Nunes, V. D., Megnin-Viggars, O., Forbes, D., Riggs, D. S., & Schnurr, P. P. (2019) · Psychotherapy · doi:10.1037/pst0000231 · Cited by 264
Treatment of Posttraumatic Stress Disorder: A State-of-the-art Review
Burback, L., Brémault-Phillips, S., Nijdam, M. J., McFarlane, A., & Vermetten, E. (2024) · Current Neuropharmacology · doi:10.2174/1570159x21666230428091433 · Cited by 208
Morgenthaler, T. I., Auerbach, S., Casey, K. R., Kristo, D., Maganti, R., Ramar, K., Zak, R., & Kartje, R. (2018) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.7178 · Cited by 230
“80,81 92 Two studies by Raskind et al. evaluated the efficacy of pra - zosin in reducing PTSD-associated nightmares in a total of 44 military veterans.”
Richards, A., Kanady, J. C., & Neylan, T. C. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-019-0486-5 · Cited by 200
“Disappointingly, a recent large RCT of prazosin for PTSD in veterans demonstrated no benefit relative to placebo and no benefit overall for either PTSD symptoms overall or for nightmares [249, 250].”
BackgroundTreatment Guidelines for PTSD: A Systematic Review
Martin, A., Naunton, M., Kosari, S., Peterson, G., Thomas, J., & Christenson, J. K. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10184175 · Cited by 181
“Therefore, there is a need for more well-designed RCTs to establish the true clinical efficacy of targeted treatments for nightmares in PTSD. Author Contributions: Conceptualization, M.N., S.K., J.T., A.M.; methodology, M.N., S.K., J.T. and A.M.; formal analysis, A.M.; investigation, A.M., J.K.C.; writing—original dra…”
BackgroundResultDepartment of Veterans Affairs Cooperative Studies Program (#575B) and Million Veteran Program, Gelernter, J., Sun, N., Polimanti, R., Pietrzak, R., Levey, D. F., Bryois, J., Lu, Q., Hu, Y., Li, B., et al. (2019) · Nature Neuroscience · doi:10.1038/s41593-019-0447-7 · Cited by 200
Self-citationNoradrenergic Modulation of Fear Conditioning and Extinction
Giustino, T. F., & Maren, S. (2018) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2018.00043 · Cited by 186
Aetiology and treatment of nightmare disorder: State of the art and future perspectives
Gieselmann, A., Ait Aoudia, M., Carr, M., Germain, A., Gorzka, R., Holzinger, B., Kleim, B., Krakow, B., Kunze, A. E., Lancee, J., et al. (2019) · Journal of Sleep Research · doi:10.1111/jsr.12820 · Cited by 195
“, 2018) and another trial in which patients returned to their baseline levels after treatment was discontinued (Raskind et al., 2018).”
BackgroundInfluentialThe Neurobiology and Pharmacotherapy of Posttraumatic Stress Disorder
Abdallah, C. G., Averill, L. A., Akiki, T. J., Raza, M., Averill, C. L., Gomaa, H., Adikey, A., & Krystal, J. H. (2019) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010818-021701 · Cited by 167
Neuropsychiatric Complications of COVID-19
Nakamura, Z. M., Nash, R. P., Laughon, S. L., & Rosenstein, D. L. (2021) · Current Psychiatry Reports · doi:10.1007/s11920-021-01237-9 · Cited by 164
Hoskins, M. D., Bridges, J., Sinnerton, R., Nakamura, A., Underwood, J. F. G., Slater, A., Lee, M. R. D., Clarke, L., Lewis, C., Roberts, N. P., et al. (2021) · European Journal of Psychotraumatology · doi:10.1080/20008198.2020.1802920 · Cited by 127
“Active drug PTSD symptoms Prazosin 10 studies (Ahmadpanah et al., 2014; Germain et al., 2012; Petrakis et al., 2016; Raskind et al., 2003; Raskind et al., 2007; Raskind et al., 2013; Raskind et al., 2018; Simpson et al., 2015; Taylor et al., 2008; Van Liempt et al., 2012), n = 652, SMD = −0.”
BackgroundInfluentialRecent Advancements in Treating Sleep Disorders in Co-Occurring PTSD
Colvonen, P. J., Straus, L. D., Stepnowsky, C., McCarthy, M. J., Goldstein, L. A., & Norman, S. B. (2018) · Current Psychiatry Reports · doi:10.1007/s11920-018-0916-9 · Cited by 113
Contribution of sleep deprivation to suicidal behaviour: A systematic review
Porras-Segovia, A., Pérez-Rodríguez, M. M., López-Esteban, P., Courtet, P., Barrigón M, M. L., López-Castromán, J., Cervilla, J. A., & Baca-García, E. (2019) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2018.12.005 · Cited by 97
Dreams and nightmares in healthy adults and in patients with sleep and neurological disorders
Siclari, F., Valli, K., & Arnulf, I. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30275-1 · Cited by 98
Pharmacotherapy for post traumatic stress disorder (PTSD)
Williams, T., Phillips, N. J., Stein, D. J., & Ipser, J. (2026) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002795.pub4 · Cited by 98
Pharmacotherapy for post traumatic stress disorder (PTSD)
Williams, T., Phillips, N. J., Stein, D. J., & Ipser, J. C. (2022) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002795.pub3 · Cited by 73
Sleep in PTSD: Treatment approaches and outcomes
Miller, K. E., Brownlow, J. A., & Gehrman, P. R. (2020) · Current Opinion in Psychology · doi:10.1016/j.copsyc.2019.08.017 · Cited by 87
Yücel, D. E., van Emmerik, A. A. P., Souama, C., & Lancee, J. (2020) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2019.101248 · Cited by 85
Posttraumatic Stress Disorder and Anxiety-Related Conditions
Williamson, J. B., Jaffee, M. S., & Jorge, R. E. (2021) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000001054 · Cited by 88
The History and Applications of the Veterans RAND 12-Item Health Survey (VR-12)
Selim, A. J., Rothendler, J. A., Qian, S. X., Bailey, H. M., & Kazis, L. E. (2022) · Journal of Ambulatory Care Management · doi:10.1097/jac.0000000000000420 · Cited by 79
“Finally, veterans who were randomly assigned to the prazosin group for posttraumatic stress disorder had no significant differences in any of the research results, including the VR-12 (Raskind et al., 2018).”
Bschor, T., Nagel, L., Unger, J., Schwarzer, G., & Baethge, C. (2024) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2024.0994 · Cited by 84
Management of nightmares in patients with posttraumatic stress disorder: current perspectives
El-Solh, A. (2018) · Nature and Science of Sleep · doi:10.2147/nss.s166089 · Cited by 79
“SSRIs are considered first-line treatment for all four-symp-tom clusters associated with PTSD.”
InfluentialWeber, F. C., & Wetter, T. C. (2021) · Neuropsychobiology · doi:10.1159/000517329 · Cited by 76
Nightmare Disorder and Isolated Sleep Paralysis
Stefani, A., & Högl, B. (2021) · Neurotherapeutics · doi:10.1007/s13311-020-00966-8 · Cited by 66
Neurobiology and Treatment of Posttraumatic Stress Disorder
Shalev, A. Y., Cho, D., & Marmar, C. R. (2024) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20240536 · Cited by 82
Top Ten Tips Palliative Care Clinicians Should Know About Psychopharmacology
Riordan, P. A., Briscoe, J. G., Uritsky, T. J., Jones, C. A., & Webb, J. A. (2019) · Journal of Palliative Medicine · doi:10.1089/jpm.2019.0106 · Cited by 63
“75 Thus, the data remain inconclusive as to whether certain patients would benefit from treatment with prazosin as previous studies had shown efficacy.”
Rasmusson, A. M., & Pineles, S. L. (2018) · Current Psychiatry Reports · doi:10.1007/s11920-018-0908-9 · Cited by 65
Are There Effective Psychopharmacologic Treatments for PTSD?
Akiki, T. J., & Abdallah, C. G. (2018) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.18ac12473 · Cited by 60
Off-Label Medication: From a Simple Concept to Complex Practical Aspects
Rusz, C.-M., Ősz, B.-E., Jîtcă, G., Miklos, A., Bătrînu, M.-G., & Imre, S. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph181910447 · Cited by 58
“Prazosin Indication Treatment of arterial hypertension Post-traumatic stress disorders [32]”
BackgroundPiantino, J. A., Iliff, J. J., & Lim, M. M. (2021) · Biological Psychiatry · doi:10.1016/j.biopsych.2021.06.025 · Cited by 66
175 Years of Progress in PTSD Therapeutics: Learning From the Past
Stein, M. B., & Rothbaum, B. O. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.17080955 · Cited by 53
Self-citationPrazosin for treatment of post-traumatic stress disorder: a systematic review and meta-analysis
Reist, C., Streja, E., Tang, C. C., Shapiro, B., Mintz, J., & Hollifield, M. (2021) · CNS Spectrums · doi:10.1017/s1092852920001121 · Cited by 56
“A m on g al lo ut co m es ,n o ad ve rs e ef fe ct w as de m on st ra te d an d al ld at a w as ob ta in ed w it h re sp ec t to th at ou tc om e m ea su re . even with inclusion of Raskind et al.15 Did the “negative finding” in that study reflect poor outcomes in patients treated with prazosin?”
BackgroundResultInfluentialSelf-citationInvolvement of the brain–heart axis in the link between PTSD and cardiovascular disease
Seligowski, A. V., Webber, T. K., Marvar, P. J., Ressler, K. J., & Philip, N. S. (2022) · Depression and Anxiety · doi:10.1002/da.23271 · Cited by 59
Management of Posttraumatic Stress Disorder
Ostacher, M. J., & Cifu, A. S. (2019) · JAMA · doi:10.1001/jama.2018.19290 · Cited by 55
Sleep Disorders in Patients With Posttraumatic Stress Disorder
El-Solh, A., Riaz, U., & Roberts, J. (2018) · CHEST Journal · doi:10.1016/j.chest.2018.04.007 · Cited by 58
Cognitive impairment and World Trade Centre-related exposures
Clouston, S., Hall, C. B., Kritikos, M., Bennett, D. A., DeKosky, S. T., Edwards, J. D., Finch, C. E., Kreisl, W. C., Mielke, M. M., Peskind, E. R., et al. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-021-00576-8 · Cited by 56
Self-citationTreatment of posttraumatic stress disorder: Focus on pharmacotherapy
Ehret, M. (2019) · Mental Health Clinician · doi:10.9740/mhc.2019.11.373 · Cited by 53
“This may have interfered with the mechanism of prazosin or masked its possible beneficial effects.(42) With so many”
BackgroundZhang, Y., Ren, R., Sanford, L. D., Yang, L., Ni, Y.-N., Zhou, J., Zhang, J., Wing, Y. K., Shi, J., Lu, L., et al. (2019) · Sleep Medicine · doi:10.1016/j.sleep.2019.06.010 · Cited by 56
“In addition, some recent published studies [15,31,32], especially the PACT trial which had a large sample size [15], add substantive new data and insights into the likely effects of prazosin, yielding a different pooled effect size compared with previous metaanalysis contributions [19,20,22].”
BackgroundResultInfluentialGrillon, C., & Ernst, M. (2020) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2020.09.024 · Cited by 52
Locus coeruleus toggles reciprocal prefrontal firing to reinstate fear
Giustino, T. F., Fitzgerald, P. J., Ressler, R. L., & Maren, S. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1814278116 · Cited by 52
MacKay, M., Yang, B. H., Dursun, S. M., & Baker, G. B. (2023) · Current Neuropharmacology · doi:10.2174/1570159x21666230222092029 · Cited by 56
“…such as the use of selective serotonin reuptake inhibitors (SSRIs), often fail to improve many of the target symptoms of PTSD. Prazosin, an α 1 -adrenoreceptor antagonist, was a promising candidate, particularly for reducing the occurrence of nightmares and other sleep-related symptoms [138].”
BackgroundSleep and PTSD in the Military Forces: A Reciprocal Relationship and a Psychiatric Approach
Saguin, E., Gomez-Merino, D., Sauvet, F., Leger, D., & Chennaoui, M. (2021) · Brain Sciences · doi:10.3390/brainsci11101310 · Cited by 50
Malikowska‐Racia, N., & Sałat, K. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.02.001 · Cited by 52
Huang, Z.-D., Zhao, Y.-F., Li, S., Gu, H.-Y., Lin, L., Yang, Z.-Y., Niu, Y., Zhang, C., & Luo, J. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00559 · Cited by 60
The influence of sleep on fear extinction in trauma-related disorders
Pace-Schott, E. F., Seo, J., & Bottary, R. M. (2022) · Neurobiology of Stress · doi:10.1016/j.ynstr.2022.100500 · Cited by 54
Predicting and Managing Treatment Non-response in Posttraumatic Stress Disorder
Fonzo, G. A., Federchenco, V., & Lara, A. (2020) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-020-00203-1 · Cited by 44
An insight on medicinal attributes of pyrimidine scaffold: An updated review
Vyas, A., Sahu, B., Pathania, S., Nandi, N. K., Chauhan, G., Asati, V., & Kumar, B. (2022) · Journal of Heterocyclic Chemistry · doi:10.1002/jhet.4593 · Cited by 49
Waltman, S. H., Shearer, D. S., & Moore, B. A. (2018) · Current Psychiatry Reports · doi:10.1007/s11920-018-0971-2 · Cited by 49
Perez, D. M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24044188 · Cited by 47
Yabuki, Y., & Fukunaga, K. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20153614 · Cited by 47
“Gabapentin (Calcium blocker) Improvement [88] Relief of anxiety response [106] Prazosin (Alpha blocker) Improvement [89,90], Not effective [91] Relief of fear response [107], facilitation of fear extinction [108] Topiramate (Anticonvulsant) Improvement [92,93] Facilitation of fear extinction [109] Nabilone (Cannabinoi…”
BackgroundSleep therapeutics and neuropsychiatric illness
Krystal, A. D. (2019) · Neuropsychopharmacology · doi:10.1038/s41386-019-0474-9 · Cited by 46
“Prazosin is the only agent with evidence of efficacy for the treatment of nightmares, although a recent large multi-site study calls that into question [58].”
BackgroundBajor, L. A., Balsara, C., & Osser, D. N. (2022) · Psychiatry Research · doi:10.1016/j.psychres.2022.114840 · Cited by 43
PTSD: Past, present and future implications for China
Zhou, Y., Shang, Z., Zhang, F., Wu, L., Sun, L., Jia, Y., Yu, H., & Liu, W. (2021) · Chinese Journal of Traumatology · doi:10.1016/j.cjtee.2021.04.011 · Cited by 45
Trauma-Associated Sleep Disorder: A Posttraumatic Stress/REM Sleep Behavior Disorder Mash-Up?
Feemster, J. C., Smith, K. L., McCarter, S. J., & Louis, E. K. S. (2019) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.7642 · Cited by 44
“45 In our patient, melatonin was also ineffective, at least when dosed to the aver - age effective dose of 6 mg nightly.”
Bourassa, K. J., Hendrickson, R. C., Reger, G. M., & Norr, A. M. (2020) · Journal of Traumatic Stress · doi:10.1002/jts.22637 · Cited by 45
“The results of two studies showed that treatment decreased tonic cardiovascular functioning (Bourassa, Stevens, et al., 2020; Raskind et al., 2018;)”
BackgroundResultInfluentialSeligowski, A. V., Misganaw, B., Duffy, L., Ressler, K. J., & Guffanti, G. (2022) · American Journal of Psychiatry · doi:10.1176/appi.ajp.21111113 · Cited by 43
DePierro, J. M., Lepow, L., Feder, A., & Yehuda, R. (2019) · Biological Psychiatry · doi:10.1016/j.biopsych.2019.07.009 · Cited by 43
“(29)), though a recent large scale study did not show efficacy for prazosin above placebo in moderating nightmare severity (30).”
BackgroundMcCall, W. V., Pillai, A., Case, D., McCloud, L., Nolla, T., Branch, F., Youssef, N. A., Moraczewski, J., Tauhidul, L., Pandya, C. D., et al. (2018) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000968 · Cited by 41
Pharmacological Management of Nightmares Associated with Posttraumatic Stress Disorder
Geldenhuys, C., van den Heuvel, L. L., Steyn, P., & Seedat, S. (2022) · CNS Drugs · doi:10.1007/s40263-022-00929-x · Cited by 39
“Prazosin remains the agent with the strongest evidence base for reducing PTNs, with several controlled trials and two positive meta-analyses.”
MethodResultInfluentialUntangling PTSD and TBI: Challenges and Strategies in Clinical Care and Research
Hendrickson, R. C., Schindler, A. G., & Pagulayan, K. F. (2018) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-018-0908-5 · Cited by 42
Sleep Disturbances and Suicidality in Posttraumatic Stress Disorder: An Overview of the Literature
Weber, F. C., Norra, C., & Wetter, T. C. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00167 · Cited by 40
“These findings are in line with a recent multi-center randomized trial on the effect of prazosin in veterans with chronic PTSD, which revealed no effects of prazosin on nightmares or sleep quality (73).”
BackgroundResultStein, M. B., Jain, S., Simon, N. M., West, J. C., Marvar, P. J., Bui, É., He, F., Benedek, D. M., Cassano, P., Griffith, J. L., et al. (2021) · Biological Psychiatry · doi:10.1016/j.biopsych.2021.05.012 · Cited by 39
Self-citationNoradrenergic circuits and signaling in substance use disorders
Downs, A. M., & McElligott, Z. A. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.108997 · Cited by 38
Sleep and psychiatric disorders: Bidirectional interactions and shared neurobiological mechanisms
Hyndych, A., Koval, K., Dzeruzhynska, N., & Mader, E. C. (2025) · PLOS mental health. · doi:10.1371/journal.pmen.0000531 · Cited by 39
“For nightmares and REM-related hyperarousal, prazosin shows mixed efficacy—positive RCTs demonstrating sleep and nightmare improvements [219,220] versus a large negative trial [221]— but remains a targeted option for select patients.”
Zhang, Y., Ren, R., Vitiello, M. V., Yang, L., Zhang, H., Shi, Y., Sanford, L. D., & Tang, X. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104717 · Cited by 37
Gasparyan, A., Navarro, D., Navarrete, F., & Manzanares, J. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109211 · Cited by 38
Trauma Associated Sleep Disorder: Clinical Developments 5 Years After Discovery
Brock, M. S., Powell, T. A., Creamer, J. L., Moore, B. A., & Mysliwiec, V. (2019) · Current Psychiatry Reports · doi:10.1007/s11920-019-1066-4 · Cited by 36
Evaluation of suvorexant for trauma-related insomnia
Mellman, T. A., Birku, K., Sandhu, I., Lavela, P., & Kobayashi, I. (2022) · SLEEP · doi:10.1093/sleep/zsac068 · Cited by 35
Self-citationMcCall, A., Forouhandehpour, R., Celebi, S., Richard-Malenfant, C., Hamati, R., Guimond, S., Tuominen, L. J., Weinshenker, D., Jaworska, N., McQuaid, R. J., et al. (2024) · Biological Psychiatry · doi:10.1016/j.biopsych.2024.01.013 · Cited by 32
Statistical analyses of ordinal outcomes in randomised controlled trials: a scoping review
Selman, C. J., Lee, K. J., Ferguson, K. N., Whitehead, C. L., Manley, B. J., & Mahar, R. K. (2024) · Trials · doi:10.1186/s13063-024-08072-2 · Cited by 39
Mansour, M., Joseph, G. R., Joy, G. K., Khanal, S., Dasireddy, R. R., Menon, A., Mason, I. B., Kataria, J., Patel, T., & Modi, S. (2023) · Cureus · doi:10.7759/cureus.44905 · Cited by 39
Narendran, R., Tollefson, S., Fasenmyer, K., Paris, J., Himes, M. L., Lopresti, B. J., Ciccocioppo, R., & Mason, N. S. (2019) · Biological Psychiatry · doi:10.1016/j.biopsych.2019.02.017 · Cited by 34
Translational approaches to influence sleep and arousal
Brown, R. E., Spratt, T. J., & Kaplan, G. B. (2022) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2022.05.002 · Cited by 33
“trial showed no benefit for nightmares or for improving sleep quality (Raskind et al., 2018).”
Potential causal association between gut microbiome and posttraumatic stress disorder
He, Q., Wang, W., Xu, D., Xiong, Y., Tao, C., You, C., Ma, L., & Ma, J. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-02765-7 · Cited by 33
Dream enactment behavior: review for the clinician
Baltzan, M., Yao, C. W., Rizzo, D., & Postuma, R. (2020) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.8734 · Cited by 32
Using Prazosin to Treat Posttraumatic Stress Disorder and Associations: A Systematic Review
Paiva, H. S., Filho, I. J. Z., & Cais, C. F. D. S. (2021) · Psychiatry Investigation · doi:10.30773/pi.2020.0411 · Cited by 31
Acute sleep interventions as an avenue for treatment of trauma-associated disorders
Swift, K. M., Thomas, C. L., Balkin, T. J., Lowery‐Gionta, E. G., & Matson, L. M. (2022) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.10074 · Cited by 31
Davenport, N. D., & Werner, J. K. (2022) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.10338 · Cited by 32
Sleep Disturbances Associated With Posttraumatic Stress Disorder
So, C. J., Miller, K. E., & Gehrman, P. R. (2023) · Psychiatric Annals · doi:10.3928/00485713-20231012-01 · Cited by 29
Fernandes, S. N., Zuckerman, E., Miranda, R., & Baroni, A. (2020) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2020.08.009 · Cited by 34
Treatment of Psychiatric Problems After Traumatic Brain Injury
Fann, J. R., Quinn, D. K., & Hart, T. (2021) · Biological Psychiatry · doi:10.1016/j.biopsych.2021.07.008 · Cited by 33
Autonomic activity, posttraumatic and nontraumatic nightmares, and PTSD after trauma exposure
Mäder, T., Oliver, K. I., Daffre, C., Kim, S., Orr, S. P., Lasko, N. B., Seo, J., Kleim, B., & Pace-Schott, E. F. (2021) · Psychological Medicine · doi:10.1017/s0033291721002075 · Cited by 32
“…for current pharmacological treatments of PTSD and nightmares, which mainly rely on medication designed to reduce sympathetic activity, such as prazosin (Gieselmann et al., 2019; Morgenthaler et al., 2018; Raskind et al., 2018; Reist et al., 2020; Yücel, van Emmerik, Souama, & Lancee, 2020).”
So how special is special K? A systematic review and meta-analysis of ketamine for PTSD RCTs
Borgogna, N. C., Owen, T., Vaughn, J., Johnson, D. A., Aita, S. L., & Hill, B. D. (2024) · European Journal of Psychotraumatology · doi:10.1080/20008066.2023.2299124 · Cited by 27
“These agents show limited therapeutic bene fi t for PTSD symptoms in modern placebo-controlled randomized control trials (RCTs; e.g. Krystal et al., 2011; Raskind et al., 2018).”
BackgroundTherapeutic Management of Nightmares: Practice Guide for Imagery Rehearsal Therapy (IRT)
Romier, A., Clerici, E., Stern, É., Maruani, J., & Geoffroy, P. A. (2024) · Current Sleep Medicine Reports · doi:10.1007/s40675-024-00287-8 · Cited by 27
“In contrast to those positive result, a recent publication has led to a reassessment of the recommendation for Prazo-sin use in nightmare disorder [74].”
Yang, J., Xie, Z., Jin, L. Y., Chen, X., & Le, Z. (2022) · Organic & Biomolecular Chemistry · doi:10.1039/d2ob00219a · Cited by 24
Skeie-Larsen, M., Stave, R., Grønli, J., Bjorvatn, B., Wilhelmsen‐Langeland, A., Zandi, A., & Pallesen, S. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20010777 · Cited by 27
“Furthermore, only two [41,75] of the fourteen studies reported a priori power calculations.”
BackgroundMethodInfluentialSleep management in posttraumatic stress disorder: a systematic review and meta-analysis
Maher, A. R., Apaydin, E. A., Hilton, L. G., Chen, C., Troxel, W., Hall, O., Azhar, G. S., Larkin, J., Motala, A., & Hempel, S. (2021) · Sleep Medicine · doi:10.1016/j.sleep.2021.08.016 · Cited by 25
Treatment of Sleep Comorbidities in Posttraumatic Stress Disorder
Brownlow, J. A., Miller, K. E., & Gehrman, P. (2020) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-020-00222-y · Cited by 25
Stanislawski, M. A., Stamper, C. E., Stearns‐Yoder, K. A., Hoisington, A. J., Brostow, D. P., Forster, J. E., Postolache, T. T., Lowry, C. A., & Brenner, L. A. (2021) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2021.100346 · Cited by 25
“It is also inherently challenging to classify medications into their predominant therapeutic indications, as numerous medications can be used to treat different conditions (Raskind et al., 2018).”
BackgroundQue, J., Shi, L., Yan, W., Chen, S., Wu, P., Sun, S., Yuan, K., Liu, Z., Zhu, Z., Fan, J.-Y., et al. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.02.033 · Cited by 24
Self-citationHargrave, A. S., Sumner, J. A., Ebrahimi, R., & Cohen, B. E. (2022) · Current Cardiology Reports · doi:10.1007/s11886-022-01809-y · Cited by 24
Ferrafiat, V., Soleimani, M., Chaumette, B., Martínez, A., Guilé, J.-M., Keeshin, B. R., & Gérardin, P. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00724 · Cited by 24
“No significant differences were reported at 26 weeks in nightmares and sleep disorders between the prazosin group and the placebo group (33).”
BackgroundThe Impact of Climate Change on Older Adults’ Mental Health: A Primer for Clinicians
Seritan, A. L. (2023) · OBM Geriatrics · doi:10.21926/obm.geriatr.2304254 · Cited by 25
Jain, R., Chepke, C., Davis, L. L., McIntyre, R. S., & Raskind, M. A. (2024) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.plunaro2417ah · Cited by 23
Self-citationAlpha-Adrenergic Receptors in PTSD — Failure or Time for Precision Medicine?
Ressler, K. J. (2018) · New England Journal of Medicine · doi:10.1056/nejme1716724 · Cited by 23
Telephone‐guided imagery rehearsal therapy for nightmares: Efficacy and mediator of change
Lancee, J., Effting, M., & Kunze, A. E. (2020) · Journal of Sleep Research · doi:10.1111/jsr.13123 · Cited by 22
“The efficacy of prazosin treatment for nightmares has mainly been tested for post-traumatic nightmares, and has recently been under debate because a large-scale trial could not detect any relevant treatment effects (Morgenthaler et al., 2018; Raskind et al., 2018).”
BackgroundChan, C., Lai, C.-Y., & Wang, C. (2020) · Organic & Biomolecular Chemistry · doi:10.1039/d0ob01507e · Cited by 21
Moore, B. A., Pujol, L. A. M., Waltman, S. H., & Shearer, D. S. (2021) · Current Psychiatry Reports · doi:10.1007/s11920-020-01220-w · Cited by 20
Metadata
- Authors
- Raskind, M. A., Peskind, E. R., Chow, B., Harris, C., Davis-Karim, A., Holmes, H. A., Hart, K. L., McFall, M., Mellman, T. A., Reist, C., Romesser, J., Rosenheck, R., Shih, M.-C., Stein, M. B., Swift, R., Gleason, T., Lu, Y., & Huang, G. D.
- Affiliations
- University of Washington (US)
- From the Veterans Affairs (VA) Northwest Network Mental Illness Research, Education, and Clinical Center (M.A.R., E.R.P., H.A.H., K.L.H., M.M.) and the Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine (M.A.R., E.R.P., M.M.), Seattle; VA Cooperative Studies Program Coordinating Center, Palo Alto (B.C., M.-C.S., Y.L.), VA Long Beach Healthcare System, Department of Human Behavior, University of California, Irvine (C.R.), the Department of Health Research...
- Howard University (US)
- United States Department of Veterans Affairs (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-02-08
- Volume
- 378
- Issue
- 6
- Pages
- 507-517
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2789959403
- Cited by
- 342
- References
- 31
- Citations by year
- 2026: 34 · 2025: 31 · 2024: 44 · 2023: 25 · 2022: 49 · 2021: 39 · 2020: 51 · 2019: 40 · 2018: 28
- FWCI
- 46.32
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- VA Cooperative Studies Program.
- Topics
- Social Sciences › Psychology › Clinical Psychology › Posttraumatic Stress Disorder Research
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Sleep and related disorders
- Health Sciences › Medicine › Clinical Neurology › Traumatic Brain Injury Research
- Keywords
- prazosin, post-traumatic stress disorder, military veterans, nightmares, chronic PTSD, alpha-blockers, sleep quality, blood pressure, adverse effects, PTSD pharmacotherapy, sleep disorders, sleep quality index, Clinician-Administered PTSD Scale, Clinical Global Impression of Change, dose escalation
- MeSH terms
- Adult, Combined Modality Therapy, Dose-Response Relationship, Drug, Double-Blind Method, Dreams, Female, Hospitals, Veterans, Humans, Male, Middle Aged, Prazosin, Psychiatric Status Rating Scales, Psychotherapy, Sleep, Sleep Wake Disorders, Stress Disorders, Post-Traumatic, United States, Veterans, Treatment Failure, Adrenergic alpha-1 Receptor Antagonists, Suicidal Ideation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.